Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1600 1645 1651 1684 1761 1791
This examiner grants 55% of resolved cases
Grant Carson Currens is an examiner in Tech Center 1700 and Art Unit 1600. He has 152 resolved cases and an allowance rate of 54.6 percent. This moderate rate suggests a balanced examination process. However, the standout figure is the interview lift of 62.5 percent. This is an extraordinary value, suggesting that interviews are highly successful in moving a case toward an allowance.
The median time to allowance is 1156 days, which is a standard duration for 152 resolved cases. This timeline indicates a typical prosecution cycle in Tech Center 1700. The 62.5 percent lift is a critical data point, as it suggests that the path to a grant is significantly smoothed by direct verbal communication with the examiner. Without an interview, the odds of success appear much lower.
For practitioners, the 62.5 percent lift is a mandate to request an interview at the earliest opportunity. While the 54.6 percent allowance rate is decent, the lift is the primary driver of success in the 152 resolved cases. The 1156-day median pendency means that applicants should be prepared for a multi-year process, but the high effectiveness of interviews provides a clear strategy for success in Art Unit 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18562933 | MICROORGANISM PRODUCING PURINE NUCLEOTIDES AND METHOD FOR PRODUCING PURINE NUCLEOTIDES USING THE SAME | Final Rejection | CJ CHEILJEDANG CORPORATION |
| 18430769 | METHOD FOR REMOVING POLYCYCLIC AROMATIC HYDROCARBONS WITH BACTERIAL STRAIN | Non-Final OA | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS |
| 18713947 | COMPOSITIONS AND METHODS FOR INHIBITING SEIZURES | Non-Final OA | The Regents of the University of California |
| 18252271 | FULL-LENGTH HUMAN IMMUNOGLOBULIN G ANTIBODY LIBRARIES FOR SURFACE DISPLAY AND SECRETION IN SACCHAROMYCES CEREVISIAE | Non-Final OA | MERCK SHARP & DOHME LLC |
| 18735444 | BACILLUS VELEZENSIS AND USE THEREOF | Non-Final OA | CHINA AGRICULTURAL UNIVERSITY |
| 18718005 | NEMATODE-SEALED CAPSULE, METHOD FOR PRODUCING NEMATODE-SEALED CAPSULE, AND USE OF NEMATODE-SEALED CAPSULE | Non-Final OA | NATIONAL INSTITUTES FOR QUANTUM SCIENCE AND TECHNOLOGY |
| 18855457 | COMPLEMENT-DEPENDENT CYTOTOXICITY METHODS | Non-Final OA | AMGEN INC. |
| 17311048 | GENETICALLY ENGINEERED CYANOBACTERIA FOR GROWTH IN UNSTERILIZED CONDITIONS USING ANTIBIOTIC-FREE SELECTION | Final Rejection | Nanyang Technological University |
| 18698893 | METHOD AND COMPOSITION FOR INHIBITING MELANOIDIN FORMATION IN A YEAST PROPAGATION PROCESS | Non-Final OA | BL Technologies, Inc. |
| 18231982 | FORMULATIONS COMPRISING GLUCOCEREBROSIDASE AND ISOFAGOMINE | Non-Final OA | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 17432725 | MICROBIAL TREATMENT | Final Rejection | Elanco US Inc. |
| 17987653 | TREATMENT OF CARDIAC ARRHYTHMIA USING BOTULINUM TOXIN | Final Rejection | Penland Foundation |
| 18002670 | PROBIOTIC COMPOSITION FOR TOPICAL USE | Final Rejection | BIOGAIA AB |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy